Imagia, a Montreal-based healthcare artificial intelligence (AI) company developing radiomics biomarkers and clinical decision support systems, today announced the completion of its acquisition of Cadens Medical Imaging (Cadens), a technology leader in medical imaging software.
“This strategic transaction will significantly accelerate Imagia’s mission of delivering AI-driven accessible personalized healthcare solutions,” said Frédéric Francis, CEO of Imagia.
Blog Apr 4, 2022
How to Bring Biomarker Testing In-House for Cancer Targeted Treatment Selection
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advan
...
Press Feb 9, 2022
Imagia Cybernetics & Canexia Health Merge to Supercharge Precision Oncology Accessibility
Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions generated from real world data, today announced its merger
...Please complete the form in order to direct your request to the appropriate department, and we will reach out as soon as possible.